Navigation Links
TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
Date:12/10/2012

PHILADELPHIA, Dec. 10, 2012 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that Dalvir Gill, PhD, has been appointed Chief Executive Officer, effective January 1, 2013. Dr. Gill will lead the independent non-profit entity, which was formed by ten healthcare and pharmaceutical companies in September to improve the quality of clinical studies and bring new medicines to patients faster by facilitating the collaboration required to solve common challenges encountered during the clinical trial process. Dr. Gill will succeed Garry Neil, MD, who has served as interim CEO of TransCelerate since the organization was formed in September. Dr. Neil will remain as Chairman of the Board of Directors for TransCelerate.

TransCelerate member organizations are currently working together on improving clinical study execution. Under this program, TransCelerate seeks to provide the following solutions for clinical trials: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.

"I am honored to lead this organization and work with the global research and development community to assess, refine and create processes to bring innovative new medicine to the public faster," said Dr. Gill.

Dr. Gill has more than 25 years of drug development experience. Prior to his appointment as CEO of TransCelerate, Dr. Gill was the President of Phase II-IV Drug Development at PharmaNet-i3, an organization specializing in drug development services. In this role, Dr. Gill was responsible for a global business spanning nearly
'/>"/>

SOURCE TransCelerate BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
2. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
3. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. John A. Orwin Joins Array BioPharma Board Of Directors
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
8. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
11. PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), a leader ... that the company's YouTube channel on SEO tips ... YouTube. The company uses YouTube as a way to ... for small businesses with much success. , "I love ... for their SEO strategies", explained Jason McDonald, director of ...
(Date:5/17/2013)... 2013 Topricin Pain Relief and ... been listed among nationally recommended over-the-counter (OTC) health ... by "U.S. News" Health in collaboration with "Pharmacy ... “No. 1 Pharmacists Recommended designation” in the “Topical ... brands, and is the only homeopathic formula to ...
(Date:5/17/2013)... 17, 2013 Dr. Sparano is Professor ... Health at the Albert Einstein College of Medicine and ... Montefiore Medical Center. He is also Associate Director ... leads the Einstein Breast Cancer Working Group, a multidisciplinary ... cancer research. He also serves as Vice Chair of ...
Breaking Biology Technology:MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... May 9 ,Takeda Pharmaceutical Company Limited, "Takeda", (TSE: ... ) today announced the,successful completion of Takeda,s cash ... to acquire all outstanding shares,of Millennium common stock ... period for the tender offer expired at 12:00,midnight, ...
... May 8 Alsius Corporation,(Nasdaq: ALUS ), ... for critically ill patients, today,announced that it will ... quarter results and provide a corporate update. Bill ... host the call beginning at,1:30 p.m. Pacific Time ...
... May 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... 2008 at,8:30 a.m. EDT to discuss the first quarter ... Officer of the Company, will host,the call. Keryx will ... release to be issued prior to the call., ...
Cached Biology Technology:Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 5Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/17/2013)... climate change may have little impact on many ... recent studies that predict their widespread extinction in ... appear in the journal Global Change Biology ... creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... forest lizards, will be hard hit by climate ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Climate change may have little impact on tropical lizards 2
... A research team at Worcester Polytechnic Institute (WPI) ... Institutes of Health (NIH) for a project aimed at ... into stem-like cells. If successful, the research could result ... tissue lost to injury, growing new organs, and curing ...
... Erec Stebbins, associate professor at The Rockefeller University, has ... Institutes of Health for a project aimed at exploiting ... into specific cells for therapeutic purposes. The award, which ... by the NIH September 3. The EUREKA program ...
... two Michigan universities have joined technical and clinical ... and computer algorithms to work in the sleep ... that a new approach to analyzing sleep fragmentation ... Joseph W. Burns, a research scientist ...
Cached Biology News:NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 2NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 3NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 4C. Erec Stebbins awarded prestigious EUREKA grant 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Macrophage-stimulating protein receptor...
Biology Products: